Frontier Medicines

Executive Summary

Frontier Medicines is a pioneering biotechnology company leveraging its proprietary chemoproteomics and AI platform to discover covalent small-molecule drugs that target previously undruggable proteins. Founded in 2018 and headquartered in South San Francisco, the company aims to translate insights from mapping the proteome into precision therapeutics for high-impact diseases. By combining covalent chemistry with advanced proteomics, Frontier can identify novel druggable sites on proteins that have eluded traditional drug discovery. The platform is broadly applicable across oncology, immunology, and other therapeutic areas, positioning the company to build a robust pipeline of first-in-class medicines. While still in the preclinical stage, Frontier's innovative approach has attracted significant interest from investors and collaborators, though the company remains private and has not disclosed specific financial details. With a strong scientific foundation and a clear focus on addressing challenging targets, Frontier Medicines represents a compelling opportunity in the precision therapeutics space.

Upcoming Catalysts (preview)

• Q3 2026Lead Optimization Data for Oncology Program60% success
• Q4 2026IND Filing for Lead Candidate40% success
• Q2 2026Strategic Partnership or Collaboration Announcement55% success